Article
Oncology
Klaudia Nowak, Kim Formenti, Jingyang Huang, Gilbert Bigras, Quincy Chu, Benjamin A. Adam, Iyare Izevbaye
Summary: Gene expression profiling (GEP) can provide complementary risk stratification information for patients with gastrointestinal stromal tumors (GIST), in addition to clinical and histological data.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Toshirou Nishida, Shinsuke Sato, Masato Ozaka, Yujiro Nakahara, Yoshito Komatsu, Masato Kondo, Haruhiko Cho, Seiichi Hirota, Tatsuo Kagimura, Yukinori Kurokawa, Yuko Kitagawa
Summary: Long-term adjuvant therapy appears to have better prognostic effects for high-risk gastrointestinal stromal tumor patients, delaying recurrence.
Article
Cell Biology
Raymond A. Isidro, Jason L. Hornick
Summary: Pleomorphism is present in approximately 4.3% of GISTs, predominantly in high-risk gastric and small intestinal GISTs, with no additional prognostic significance beyond conventional risk stratification.
Article
Oncology
Josephine K. Dermawan, Ciara Kelly, Zhidong Gao, Shaleigh Smith, Bhumika Jadeja, Samuel Singer, William D. Tap, Ping Chi, Cristina R. Antonescu
Summary: This study developed a novel genomic risk stratification model for primary gastric and small bowel GISTs, complementing traditional clinicopathologic models. A 3-tier genomic risk stratification model was proposed and compared with conventional risk stratification, suggesting that genomic risk stratification may better predict the prognosis of GIST patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Yeong Hak Bang, Min-Hee Ryu, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
Summary: This registry-based study investigated the safety and efficacy of 3-year imatinib treatment in high-risk GIST patients, and found that tumor rupture, large tumor size, and high mitotic count were associated with poor recurrence-free survival.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Tianzhu Liu, Gao Lin, Hui Peng, Lesheng Huang, Xiaosong Jiang, Hongyi Li, Kaili Cai, Jinghua Jiang, Lei Guo, Xiaohua Du, Jiahui Tang, Wanchun Zhang, Jun Chen, Yongsong Ye
Summary: GIST patients with air-fluid levels differ significantly from those without in terms of clinical characteristics, surgical procedures, and prognosis. They are more likely to undergo open surgery and targeted therapy with Imatinib mesylate, with higher rates of recurrence and death during follow-up. The Torricelli-Bernoulli sign may adversely affect the patient's prognosis.
Article
Pathology
Shaomin Hu, Lindsay Alpert, Justin M. M. Cates, Raul S. Gonzalez
Summary: Progression risk of esophageal and colonic GISTs is associated with increased mitotic activity and size >5.0 cm, while appendiceal GISTs are typically smaller with low mitotic rates.
Article
Radiology, Nuclear Medicine & Medical Imaging
Jian-Xian Lin, Fu-Hai Wang, Zu-Kai Wang, Jia-Bin Wang, Chao-Hui Zheng, Ping Li, Chang-Ming Huang, Jian-Wei Xie
Summary: The objective of this study is to develop a mitotic prediction model and preoperative risk stratification nomogram for gastrointestinal stromal tumor (GIST) based on computed tomography (CT) radiomic features. By delineating the tumor region of interest and extracting radiomic features, a radiomic model was established to predict mitotic index in GIST. A preoperative risk stratification nomogram combining radiomic features was constructed and found to be equivalent to the clinically recognized gold standard.
Article
Oncology
Kathryn E. Marqueen, Erin Moshier, Michael Buckstein, Celina Ang
Summary: Neoadjuvant systemic therapy for localized GIST may provide a modest survival benefit and lower risk of 90-day postoperative mortality, without a significant difference in achieving an R0 resection.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Maria Teresa Masucci, Maria Letizia Motti, Michele Minopoli, Gioconda Di Carluccio, Maria Vincenza Carriero
Summary: Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal neoplasms of the gastrointestinal tract. The diagnosis of GISTs is based on morphologic analysis, immunohistochemical evaluation, and genomic profiling to assess mutational status. Targeted therapy, such as tyrosine kinase inhibitors (TKIs), has significantly improved the management of unresectable or metastatic GISTs, although disease progression is common due to secondary mutations. Identification of new oncogenic mutations has opened up new frontiers for precision medicine in the treatment of GISTs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Feng Wang, Tingting Tao, Heng Yu, Yingying Xu, Zhi Yang, Xuefeng Xia, Meng Wang, Liang Zong, Wenxian Guan
Summary: Immunoinflammatory and nutritional markers, such as NLR, PLR, and OPNI, have shown potential as prognostic markers for GISTs. OPNI was identified as an independent prognostic marker associated with various clinicopathological factors, and low OPNI was linked to worse RFS.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Zhaojun Xu, Xiaobin Chen, Pengfei Li, Junli Mi, Chengwu Zhang, Chen Lin, Xiaoming Ma
Summary: This study analyzed the relationship between risk factors and prognosis of patients with gastrointestinal stromal tumor associated with gastrointestinal bleeding. Modified National Institutes of Health criteria and relapse were found to be independent risk factors for gastrointestinal stromal tumors with gastrointestinal bleeding, and gastrointestinal bleeding was associated with poor prognosis. The accuracy of Modified National Institutes of Health criteria in predicting postoperative survival status and recurrence was higher than that of Armed Forces Institute of Pathology criteria.
Article
Immunology
Jingjing Wang, Hui Ren, Wenhui Wu, Qianlin Zeng, Jingyao Chen, Juanjuan Han, Minquan Lin, Changhua Zhang, Yulong He, Mingzhe Li
Summary: The study revealed the relationship between immune infiltration and cancer stem-like properties in patients with gastrointestinal stromal tumor (GIST), with a correlation to tumor purity. The cancer stemness index can serve as a predictive biomarker for tumor metastasis and a target for drug therapy in GIST patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Surgery
Jun Young Kim, Tae Jun Kim, Dong Kyu Lee, Yang Won Min, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Ji Yeong An, Min Gew Choi, Tae Sung Sohn, Jae Moon Bae, Hye Seung Kim, Joong Hyun Ahn, Jae J. Kim
Summary: This study developed a simple risk-scoring system (RSS) to predict the malignancy potential of gastric GISTs, which includes factors such as tumor size, location, and surface changes. The RSS showed good performance in predicting high malignancy potential (HMP) after validation, helping clinicians make more informed preoperative treatment decisions.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2022)
Article
Oncology
Tian-Tian Wang, Wei-Wei Liu, Xian-Hai Liu, Rong-Ji Gao, Chun-Yu Zhu, Qing Wang, Lu-Ping Zhao, Xiao-Ming Fan, Juan Li
Summary: The study analyzed the clinicopathological and CT imaging data of 147 patients with primary gastric GISTs and found that tumor size, growth patterns, and lesion contours were predictive CT features for malignant potential.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2023)